Rothschild Asset Management Inc. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 12.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 769,000 shares of the company’s stock after selling 114,359 shares during the quarter. Rothschild Asset Management Inc. owned about 0.07% of Eli Lilly and worth $63,289,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Cardinal Capital Management lifted its stake in Eli Lilly and by 4.8% in the second quarter. Cardinal Capital Management now owns 48,461 shares of the company’s stock valued at $3,988,000 after buying an additional 2,207 shares in the last quarter. Honkamp Krueger Financial Services Inc. lifted its stake in Eli Lilly and by 1.9% in the second quarter. Honkamp Krueger Financial Services Inc. now owns 13,602 shares of the company’s stock valued at $1,119,000 after buying an additional 257 shares in the last quarter. Spinnaker Trust lifted its stake in Eli Lilly and by 1.7% in the second quarter. Spinnaker Trust now owns 2,736 shares of the company’s stock valued at $225,000 after buying an additional 46 shares in the last quarter. Country Trust Bank lifted its stake in Eli Lilly and by 0.3% in the second quarter. Country Trust Bank now owns 284,336 shares of the company’s stock valued at $23,401,000 after buying an additional 756 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in Eli Lilly and by 2.7% in the second quarter. Parkside Financial Bank & Trust now owns 4,037 shares of the company’s stock valued at $332,000 after buying an additional 106 shares in the last quarter. 75.77% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on LLY. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Deutsche Bank AG reiterated a “buy” rating and issued a $91.00 price objective (up from $90.00) on shares of Eli Lilly and in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Tuesday, July 4th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $88.27.

COPYRIGHT VIOLATION NOTICE: “Rothschild Asset Management Inc. Cuts Holdings in Eli Lilly and Company (LLY)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/17/rothschild-asset-management-inc-cuts-holdings-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company (LLY) opened at 82.44 on Friday. The firm’s 50-day moving average is $80.89 and its 200-day moving average is $82.06. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The company has a market capitalization of $86.97 billion, a PE ratio of 35.67 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the firm posted $0.86 EPS. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s dividend payout ratio is presently 90.04%.

In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the completion of the sale, the insider now directly owns 124,475,804 shares of the company’s stock, valued at approximately $10,337,715,522.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 825,000 shares of company stock valued at $68,456,650. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.